Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Prevention of PVR in RRD Repair
NCT04580147Phase 2Unknown
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in Proliferative Vitreoretinopathy (PVR). Status: unknown.
02
Drugs
aflibercept
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT04580147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580147.